Published in J Immunol on February 15, 1990
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J (1996) 6.01
Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A (1995) 3.87
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A (1990) 3.70
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A (1994) 3.30
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A (1992) 2.98
The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J (1990) 2.74
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol (1993) 2.40
Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J (1994) 2.06
Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci U S A (1995) 2.03
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. EMBO J (1995) 1.94
Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. Proc Natl Acad Sci U S A (1994) 1.72
Targeting mTOR dependency in pancreatic cancer. Gut (2014) 1.65
Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. Mol Cell Biol (1995) 1.52
Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med (1991) 1.48
Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology (1991) 1.48
Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J (1995) 1.47
Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol (1995) 1.42
Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A (1994) 1.41
The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 1.27
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother (1997) 1.24
Light-regulated, tissue-specific immunophilins in a higher plant. Proc Natl Acad Sci U S A (1994) 1.24
Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. Mol Cell Biol (1991) 1.22
Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep (2000) 1.19
The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. Mol Cell Biol (1993) 1.19
Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol (2010) 1.18
Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture. Neuroscience (2002) 1.15
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci U S A (1991) 1.10
Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett (2003) 1.10
Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol (2008) 0.99
From nature to the laboratory and into the clinic. Bioorg Med Chem (2008) 0.95
Hypersensitivity to rapamycin of BJAB B lymphoblastoid cells. Immunology (1996) 0.92
Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology (1991) 0.91
Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest (1997) 0.91
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol (1991) 0.88
FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. J Bacteriol (1992) 0.81
Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation (1994) 0.81
Expression, localisation and functional activation of NFAT-2 in normal human skin, psoriasis, and cultured keratocytes. Int J Clin Exp Med (2009) 0.76
mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. Transplantation (2016) 0.76
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. J Diabetes Res (2016) 0.75
David and Goliath: chemical perturbation of eukaryotes by bacteria. J Ind Microbiol Biotechnol (2015) 0.75
Protein Translation and Signaling in Human Eosinophils. Front Med (Lausanne) (2017) 0.75
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53
Assessing B cell diversification by antigen receptor and precursor cell analysis. Ann Immunol (Paris) (1976) 3.88
Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol (1990) 3.29
Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes (1994) 2.16
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Production of antibodies of identical idiotype but diverse immunoglobulin classes by cells derived from a single stimulated B cell. Proc Natl Acad Sci U S A (1975) 1.96
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol (1985) 1.78
Heterogeneity of the BALB/c antiphosphorylcholine antibody response at the precursor cell level. J Exp Med (1975) 1.75
Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J Biol Chem (1998) 1.73
Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med (1993) 1.67
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
The frequency of phosphorylcholine-specific B cells in conventional and germfree BALB/C mice. J Immunol (1975) 1.55
Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1. J Exp Med (1993) 1.52
Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem (1991) 1.51
FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. Proc Natl Acad Sci U S A (1991) 1.49
Differential expression of an equivalent clonotype among BALB/c and C57BL/6 mice. J Exp Med (1978) 1.49
Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med (1991) 1.48
Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. J Exp Med (1992) 1.46
The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity (2000) 1.40
Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol (1990) 1.37
The adjuvanticity of interleukin 1 in vivo. J Immunol (1983) 1.35
Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol (1998) 1.32
I-E+ nonobese diabetic mice develop insulitis and diabetes. J Exp Med (1993) 1.32
Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem (1998) 1.32
The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. J Biol Chem (1990) 1.30
Immunochemical evidence in two haplotypes for at least three D region-encoded molecules, D, L, and R. J Immunol (1981) 1.29
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 1.27
Expression of phosphorylcholine-specific B cells during murine development. J Exp Med (1977) 1.19
Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol (1999) 1.19
FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol (1989) 1.18
Regulation of azophenylarsonate-specific repertoire expression. 1. Frequency of cross-reactive idiotype-positive B cells in A/J and BALB/c mice. J Exp Med (1982) 1.17
The B-cell clonotype repertoire. Adv Immunol (1978) 1.16
The monoclonal anti-phosphorylcholine antibody response in several murine strains: genetic implications of a diverse repertoire. J Exp Med (1977) 1.15
Genetic control of diabetes and insulitis in the nonobese diabetic mouse. Pedigree analysis of a diabetic H-2nod/b heterozygote. J Immunol (1989) 1.12
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol (1991) 1.12
Heterogeneity of EBV-transformable human B lymphocyte populations. J Immunol (1986) 1.09
Reduction of serum Interleukin-1-like activity after treatment with dexamethasone. J Leukoc Biol (1985) 1.09
Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science (1993) 1.08
Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci U S A (2000) 1.08
Late acquisition of a germ line antibody specificity. Nature (1976) 1.05
New technologies for high-throughput screening. Curr Opin Chem Biol (1997) 1.02
Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol (1995) 0.98
A study of the correlation between cyclophilin binding and in vitro immunosuppressive activity of cyclosporine A and analogues. Transplant Proc (1988) 0.98
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis (1997) 0.97
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]. Dtsch Med Wochenschr (1984) 0.96
Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect Immun (1988) 0.95
Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity. Analysis in mutant clones of a T cell lymphoma. J Immunol (1994) 0.95
Human cytotoxic lymphocyte tryptase. Its purification from granules and the characterization of inhibitor and substrate specificity. J Biol Chem (1988) 0.94
FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol (1992) 0.94
Metronome in Parkinson's disease. Lancet (1996) 0.94
Genetic influences on the adjuvanticity of muramyl dipeptide in vivo. J Immunol (1982) 0.93
X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect Immun (1988) 0.93
Large, activated B cells are the primary B-cell target of 8-bromoguanosine and 8-mercaptoguanosine. Cell Immunol (1987) 0.92
The interplay of evolution and environment in B-cell diversification. Cold Spring Harb Symp Quant Biol (1977) 0.92
Idiotype-specific neonatal suppression of phosphorylcholine-responsive B cells. Eur J Immunol (1977) 0.92
Novel idiotypic and antigen-binding characteristics in two anti-dinitrophenyl monoclonal antibodies. J Exp Med (1977) 0.90
Heterogeneity of the BALB/c IgM anti-phosphorylcholine antibody response. Nature (1982) 0.90
FK-506--a novel immunosuppressant. Ann N Y Acad Sci (1993) 0.89
Neurological complications in AIDS. J Neurol (1987) 0.89
Expression of a bone marrow-associated Ly-6 determinant on the T cell population expanding in the lymph nodes of the autoimmune mouse strain MRL/Mp-lpr/lpr. J Immunol (1983) 0.89
Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. Biochem Biophys Res Commun (1992) 0.88
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol (1983) 0.88
Heterogeneity of the human phosphocholine-specific B cell repertoire. J Immunol (1984) 0.87
Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085. Neurology (1983) 0.87
Patterns of isotype commitment in human B cells: limiting dilution analysis of Epstein Barr virus-infected cells. J Immunol (1983) 0.87
The augmentation of surface Ly-6A/E molecules in activated T cells is mediated by endogenous interferon-gamma. J Immunol (1987) 0.87
The significance of cerebral atrophy for the symptomatology of Parkinson's disease. J Neurol Sci (1979) 0.87
Regulation of class II MHC molecules on human endothelial cells. Effects of IFN and dexamethasone. J Immunol (1988) 0.86
The frequency of para-azophenylarsonate and dimethylaminonapthalene-sulfonyl-specific B cells in neonatal and adult BALB/c mice. J Immunol (1977) 0.86
IL-2 induces expression of serine protease enzymes and genes in natural killer and nonspecific T killer cells. J Immunol (1989) 0.86
In vitro regulation of IgA subclass production. III. Selective transformation of IgA1 producing cells by Epstein-Barr virus. J Immunol (1987) 0.86
Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease. J Neural Transm Park Dis Dement Sect (1993) 0.85
In vitro tolerance induction of neonatal murine B cells as a probe for the study of B-cell diversification. J Exp Med (1977) 0.85
Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. J Pharmacol Exp Ther (1994) 0.85
Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity. J Immunol (1982) 0.84
The human and murine influenza-specific B cell repertoires share a common idiotope. J Immunol (1987) 0.84
Lamotrigine--antiparkinsonian activity by blockade of glutamate release? J Neural Transm Park Dis Dement Sect (1993) 0.84
Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int J Immunopharmacol (1991) 0.83
FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. Biochem Pharmacol (1991) 0.83
Idiotypic and fluorometric analysis of the antibodies that distinguish the lesion of the I-A mutant B6.C-H-2bm12. J Immunol (1983) 0.83
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol (1993) 0.82
A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia. J Infect Dis (1990) 0.82
Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. Int J Immunopharmacol (1991) 0.82